Skip to main content

hmpl-760

Generic: BTK Inhibitor HMPL-760

hmpl-760: 3 clinical trials tracked.

hmpl-760 evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about hmpl-760, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (3)

An Open-Label, Randomized, Four-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food and Proton Pump Inhibitor Rabeprazole on the Pharmacokinetics of HMPL-760 Capsules in Healthy Participants

NCT07643272Registry updated 2026-09-18·Phase 1
Completed

Primary endpoint: AUC 0-last

InterventionalRandomizedopen24 enrolledStarted 2026-06Completion 2026-081 site · ChinaHutchmed

A Phase III Randomized, Double-Blind, Positive Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT07409428Registry updated 2026-07-20·Phase 3
Recruiting

Primary endpoint: Progression-free survival (PFS)

InterventionalRandomizedquadruple240 targetStarted 2026-03Completion 2028-1250 sites · ChinaHutchmed

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT05190068Registry updated 2025-04-09·Phase 1
Completed

Primary endpoint: DLTs

Interventionalopen89 enrolledStarted 2022-01Completion 2025-0122 sites · ChinaHutchmed